<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1736">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05138562</url>
  </required_header>
  <id_info>
    <org_study_id>TUC3PII-01</org_study_id>
    <nct_id>NCT05138562</nct_id>
  </id_info>
  <brief_title>TUC3PII-01_TU2670 Phase IIa Clinical Study</brief_title>
  <official_title>A Phase IIa, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of Orally Administered TU2670 in Subjects With Mod to Severe Endometriosis-Associated Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TiumBio Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TiumBio Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Protocol for TU2670 is to investigate the efficacy, safety, pharmacokinetics (PK), and&#xD;
      pharmacodynamics (PD) of multiple doses of TU2670 in subjects with moderate to severe&#xD;
      endometriosis-associated pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment Groups and Duration:&#xD;
&#xD;
      Following a washout period of up to 12 weeks, subjects will enter a screening period of up to&#xD;
      12 weeks including an observation period consisting of a complete menstrual cycle.&#xD;
&#xD;
      Subjects will be randomly assigned in a 1:1:1:1 ratio to receive either 12 weeks of TU2670&#xD;
      320 mg QD, TU2670 240 mg QD, TU2670 120 mg QD, or matching placebo. TU2670 or a matching&#xD;
      placebo will be administered in the clinic on Day 1. Subjects in the PK subset population&#xD;
      will also receive the following additional doses in the clinic: Day 2 (after collection of&#xD;
      the 24-hour PK sample); the dose on the day scheduled for subsequent serial PK sample&#xD;
      collection (Week 4 or Week 5); and the next scheduled dose (after collection of the 24-hour&#xD;
      PK sample). All other doses can be taken by the subject at home. Following the end of&#xD;
      treatment, subjects will be followed up for safety for 12 weeks.&#xD;
&#xD;
      Statistical Methods:&#xD;
&#xD;
      All formal statistical tests will be done at the 5% 2-sided significance level. Point&#xD;
      estimates will have 2 sided 95% confidence intervals (CIs) where applicable.&#xD;
&#xD;
      Where appropriate, variables will be summarized descriptively (frequency and percent will be&#xD;
      summarized for categorical variables; n (number of available subjects), mean, standard&#xD;
      deviation [SD], median, minimum, and maximum will be presented for continuous variables) by&#xD;
      study visit and by treatment group.&#xD;
&#xD;
      Statistical summaries will be presented for the changes from baseline to each time point in&#xD;
      efficacy endpoints that it is applicable.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall pelvic pain</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to 12 weeks of treatment of the mean dysmenorrhea score (defined as mean overall pelvic pain score on menstrual bleeding days) as measured by the Numeric Rating Scale(minimum 0, maximum 10, higher score mean a worse outcome) over the past month.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean Numeric Rating Scale pain score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to 12 weeks of treatment of the mean Numeric Rating Scale pain score(minimum 0, maximum 10, higher score mean a worse outcome) for non-menstrual pelvic pain (mean Numeric Rating Scale pain score on non menstrual bleeding days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean overall pelvic pain Numeric Rating Scale pain score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to 12 weeks of treatment of the mean overall pelvic pain Numeric Rating Scale pain score (mean Numeric Rating Scale pain score(minimum 0, maximum 10, higher score mean a worse outcome) over all 28 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean Numeric Rating Scale dyspareunia score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to 12 weeks of treatment of the mean Numeric Rating Scale((minimum 0, maximum 10, higher score mean a worse outcome) dyspareunia score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rescue medication</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to 12 weeks of treatment of the use of protocol-defined rescue medication (ie, ibuprofen)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to increase of dose of rescue medication</measure>
    <time_frame>12 weeks</time_frame>
    <description>Time to increase of dose of rescue medication from 0 week to 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to decrease of dose of rescue medication</measure>
    <time_frame>12 weeks</time_frame>
    <description>Time to decrease of dose of rescue medication from 0 week to 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Biberoglu and Behrman sign and symptom scores</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to 12 weeks of treatment of the Modified Biberoglu and Behrman (mB&amp;B) sign and symptom scores(minimum 0, maximum 3, higher score mean a worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patient Global Impression of Change (minimum 1, maximum 7, higher score mean a worse outcome) at 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometriosis Health Profile-5</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to 12 weeks of treatment in the Endometriosis Health Profile-5 score(minimum 1(Never), maximum 5(Always), higher score mean a worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-Item Short Form Health Survey</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to 12 weeks of treatment of the 36-Item Short Form Health Survey(Scoring meaning is different from the questions but usually lower score mean a worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity and Activity Impairment Questionnaire: General Health</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to 12 weeks of treatment of the Work Productivity and Activity Impairment Questionnaire: General Health (Scoring meaning is different from the questions)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Bone mineral density loss</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to 12 weeks of treatment of the bone mineral density as assessed by dual-energy X-ray absorptiometry (DXA)</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 Placebo capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TU2670 High Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>320mg, QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TU2670 Medium Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>240 mg, QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TU2670 Low Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>120 mg, QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator: Placebo</intervention_name>
    <description>4 x placebo capsules, QD</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Comparator: TU2670 320mg</intervention_name>
    <description>320mg (80mg x 4), QD</description>
    <arm_group_label>TU2670 High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Comparator: TU2670 240mg</intervention_name>
    <description>240mg (80mg x 3 + placebo x 1), QD</description>
    <arm_group_label>TU2670 Medium Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Comparator: TU2670 120mg</intervention_name>
    <description>120mg (80mg x 1 + 20mg x 2 + placebo x 1), QD</description>
    <arm_group_label>TU2670 Low Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Independent Ethics Committee (IEC)-approved written informed consent/assent and&#xD;
             privacy language as per national regulations must be voluntarily obtained from the&#xD;
             subject.&#xD;
&#xD;
          -  Premenopausal female subject, 18 to 45 years, inclusive&#xD;
&#xD;
          -  Subject has moderate to severe endometriosis-related pain&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has used hormonal contraceptives or other drugs with effects on gynecological&#xD;
             endocrinology within 12 weeks&#xD;
&#xD;
          -  Subject has been nonresponsive to GnRH-agonist or antagonist therapy for the&#xD;
             management of endometriosis.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tium Bio</last_name>
    <phone>+82-31-600-1500</phone>
    <email>NCE403_TU2670@tiumbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>SiYoo Lee</last_name>
    <phone>+82-31-600-1511</phone>
    <email>siyoo@tiumbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Hradec Kralove</name>
      <address>
        <city>Hradec Králové</city>
        <state>Hradec Kralove</state>
        <zip>50005</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Mls</last_name>
      <phone>+420728489859</phone>
      <email>jan.mls.gyn@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kestr-gyn s.r.o., Gynekologicka ambulance</name>
      <address>
        <city>Náchod</city>
        <state>Nachod</state>
        <zip>54701</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Kestranek Site Address</last_name>
      <phone>+420491421883</phone>
      <email>kestra@volny.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>OB/GYN</name>
      <address>
        <city>Praha</city>
        <state>Praha 1</state>
        <zip>11000</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viktor Kacer</last_name>
      <phone>+42222245565</phone>
      <email>viktor.kacer@protonmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze, Dept. of Gynekologicko- porodnickaklinika 1.LF UK</name>
      <address>
        <city>Praha</city>
        <state>Praha 2</state>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel Calda</last_name>
      <phone>+420224967273</phone>
      <email>calda@gynstart.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Kralovske Vinohrady</name>
      <address>
        <city>Praha 10</city>
        <state>Praha</state>
        <zip>10034</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Hruda</last_name>
      <phone>+420773622730</phone>
      <email>martin.hruda@fnkv.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Hudecek</last_name>
      <phone>+420532232449</phone>
      <email>hudecek.robert@fnbrno.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NEUMED gynekologicka ambulance</name>
      <address>
        <city>Olomouc</city>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Neubert</last_name>
      <phone>+420588517332</phone>
      <email>neumed@seznam.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nemocnice Na Bulovce</name>
      <address>
        <city>Prague</city>
        <zip>18100</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michal Zikan</last_name>
      <phone>+420266083229</phone>
      <email>michal.zikan@bulovka.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Cagliari - Policlinico Universitario Duilio Casula</name>
      <address>
        <city>Monserrato</city>
        <state>Cagliari</state>
        <zip>09042</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefano Guerriero</last_name>
      <phone>+393487848668</phone>
      <email>gineca.sguerriero@tiscali.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda ospedaliero-universitaria Senese</name>
      <address>
        <city>Siena</city>
        <state>Tuscany</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabriele Centini</last_name>
      <phone>+39577585111</phone>
      <email>centini.gabriele@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florence</name>
      <address>
        <city>Florence</city>
        <zip>50129</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Elisabetta Coccia</last_name>
      <phone>+39557949926</phone>
      <email>elisabetta.coccia@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo Vercellini</last_name>
      <phone>+39255032318</phone>
      <email>paolo.vercellini@unimi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZIENDA Ospedaliero Univeritaria Di Modena</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlo Alboni</last_name>
      <phone>+39594224387</phone>
      <email>alboni.carlo@aou.mo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli IRCCS</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fiorenzo De Cicco Nardone</last_name>
      <phone>+390630155131</phone>
      <email>fiorenzo.decicconardone@policlinicogemelli.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P.O. Sant'Anna</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Saverio Danese</last_name>
      <phone>+39011313444</phone>
      <email>sdanese@cittadellasalute.to.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata Verona</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Valentino Bergamini</last_name>
      <phone>+390458122153</phone>
      <email>valentino.bergamini@aovr.veneto.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dolnośląskie Centrum Ginekologii</name>
      <address>
        <city>Wrocław</city>
        <state>Dolnośląskie</state>
        <zip>53333</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariusz Markuszewski</last_name>
      <phone>+48717213200</phone>
      <email>biuro@dcg.wroclaw.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>In Vivo sp. z o.o.</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85090</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek Szymanski</last_name>
      <phone>+48501109918</phone>
      <email>kontakt@in-vivo.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gameta Hospital</name>
      <address>
        <city>Rzeszów</city>
        <state>Lodzkie</state>
        <zip>95030</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pawel Radwan</last_name>
      <phone>+48426457777</phone>
      <email>pradwan@gameta.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Komed Centra Kliniczne</name>
      <address>
        <city>Lublin</city>
        <state>Lubelskie</state>
        <zip>20362</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek Gogacz</last_name>
      <phone>+48814402474</phone>
      <email>marek.gogacz@komed-ck.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Pro-Familia</name>
      <address>
        <city>Rzeszów</city>
        <state>Podkarpackie</state>
        <zip>35-302</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomasz Lozinski</last_name>
      <phone>+4817773700</phone>
      <email>tomasz.lozinski@pro-familia.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prywatna Klinika Położniczo-Ginekologiczna Sp. z o.o.</name>
      <address>
        <city>Białystok</city>
        <state>Podlaskie</state>
        <zip>15224</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janusz Tomaszewski</last_name>
      <phone>+48602373927</phone>
      <email>klinika.jtomaszewski@wp.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Mikołowska</name>
      <address>
        <city>Katowice</city>
        <state>Silesia</state>
        <zip>40065</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Sipinski</last_name>
      <phone>+48601444059</phone>
      <email>cmmkatowice@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Examen sp z o.o.</name>
      <address>
        <city>Skorzewo</city>
        <state>Wielkopolska</state>
        <zip>60185</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krzysztof Szymanowski</last_name>
      <phone>+48618419324</phone>
      <email>kp.szymanowski@wp.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika Leczenia Niepłodności, Ginekologii i Położnictwa Bocian</name>
      <address>
        <city>Białystok</city>
        <zip>15267</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grzegorz Mrugacz</last_name>
      <phone>+48857447700</phone>
      <email>gmrugacz@klinikabocian.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Provita Sp. z o.o.</name>
      <address>
        <city>Katowice</city>
        <zip>40611</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariusz Kiecka</last_name>
      <phone>+48327837303</phone>
      <email>m.kiecka@angelius.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika Leczenia Niepłodności, Ginekologii i Położnictwa Bocian, Fertility Clinic</name>
      <address>
        <city>Poznań</city>
        <zip>60529</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olaf Lindert</last_name>
      <phone>+48327010460</phone>
      <email>olaf.lindert@wp.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ural Research Institution of Maternity and Child Care of Russian Public Health Ministry</name>
      <address>
        <city>Ekaterinburg</city>
        <state>Sverdlovskaya Oblast</state>
        <zip>620146</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadezhda Bashmakova</last_name>
      <phone>+79122409205</phone>
      <email>dr@niiomm.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Institution of Healthcare Moscow City Clinical Hospital # 13 of Moscow Department</name>
      <address>
        <city>Moscow</city>
        <zip>115280</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felix Grigoryan</last_name>
      <phone>+70952743646</phone>
      <email>9166852535@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>FSHI Clinical Hospital #85 of FMBA</name>
      <address>
        <city>Moscow</city>
        <zip>115409</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergey Levakov</last_name>
      <phone>+74993248674</phone>
      <email>levakoff@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moscow State University of Medicine and Dentistry</name>
      <address>
        <city>Moscow</city>
        <zip>127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir Kuzmin</last_name>
      <phone>+74993905778</phone>
      <email>vnkuzmin@rambler.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SBIH Leningrad Regional Clinical Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irina Sergeeva</last_name>
      <phone>+78125927819</phone>
      <email>irina-sergeeva@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankivsk National Medical University on the basis of the municipal non-profit enterprise Ivano-Frankivsk Regional Perinatal Center of the Regional Council</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <state>Ivano-Frankivsk</state>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oksana Makarchuk</last_name>
      <phone>+380342553165</phone>
      <email>o_makarchuk@ukr.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal non-commercial enterprise Vinnytsia City Clinical Hospital &quot;Center of Mother and the Child</name>
      <address>
        <city>Vinnytsia</city>
        <state>Vinnitsia</state>
        <zip>21019</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andriy Hryhorenko</last_name>
      <phone>+380674302263</phone>
      <email>ahryhorenko@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Nonprofit Enterprise Maternity Hospital#4 of Zaporizhzhya Municipal Council</name>
      <address>
        <city>Zaporizhzhya</city>
        <state>Zaporizhzhya Oblast</state>
        <zip>69065</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galyna Reznichenko</last_name>
      <phone>+380617641734</phone>
      <email>reznichenkog17@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Scientific Institution Center for Innovative Medical Technologies of the National Academy of Sciences of Ukraine</name>
      <address>
        <city>Kiev</city>
        <zip>04053</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tetyana Tatarchuk</last_name>
      <phone>+380442721072</phone>
      <email>prof.tatarchuk@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyiv city clinical hospital #9, Department of gynecology</name>
      <address>
        <city>Kyiv</city>
        <zip>04112</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nataliya Zakharenko</last_name>
      <phone>+380444400366</phone>
      <email>gynec9@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lviv city clinical hospital #4</name>
      <address>
        <city>Lviv</city>
        <zip>79005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadiia Ilkiv</last_name>
      <phone>+380986445126</phone>
      <email>ngilkiv@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Danylo Halytskyy Lviv national medical university</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serhiy Shurpyak</last_name>
      <phone>+380322766162</phone>
      <email>shurpyak_serhiy@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Private Small-Scale Enterprise Medical Centre Pulse</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21001</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oksana Taran</last_name>
      <phone>+380432612696</phone>
      <email>taranoa@ukr.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 25, 2021</study_first_submitted>
  <study_first_submitted_qc>November 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

